[HTML][HTML] HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer
EC de Heer, M Jalving, AL Harris - The Journal of clinical …, 2020 - Am Soc Clin Investig
Hypoxia-inducible factors (HIFs) and the HIF-dependent cancer hallmarks angiogenesis and
metabolic rewiring are well-established drivers of breast cancer aggressiveness, therapy …
metabolic rewiring are well-established drivers of breast cancer aggressiveness, therapy …
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments
Eighteen years ago, the EORTC PET criteria standardized for the first time response
assessment by FDG PET. Response assessment by FDG PET has been further developed …
assessment by FDG PET. Response assessment by FDG PET has been further developed …
[HTML][HTML] Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab …
G Gebhart, LE Lamberts, Z Wimana, C Garcia… - Annals of oncology, 2016 - Elsevier
Background Only human epidermal growth factor receptor (HER) 2 status determined by
immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) has been …
immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) has been …
Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives
Angiogenesis is one of the hallmarks of cancer and a crucial requisite in the development of
tumors. Interrupting this process by blocking the vascular endothelial growth factor (VEGF) …
tumors. Interrupting this process by blocking the vascular endothelial growth factor (VEGF) …
Early prediction of treatment response to neoadjuvant chemotherapy based on longitudinal ultrasound images of HER2-positive breast cancer patients by Siamese …
Y Liu, Y Wang, Y Wang, Y Xie, Y Cui, S Feng… - …, 2022 - thelancet.com
Background Early prediction of treatment response to neoadjuvant chemotherapy (NACT) in
patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer can …
patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer can …
Human epidermal growth factor receptor 2–targeting [68Ga] Ga-ABY-025 PET/CT predicts early metabolic response in metastatic breast cancer
A Alhuseinalkhudhur, H Lindman, P Liss… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Imaging using the human epidermal growth factor receptor 2 (HER2)–binding tracer 68Ga-
labeled ZHER2: 2891-Cys-MMA-DOTA ([68Ga] Ga-ABY-025) was shown to reflect HER2 …
labeled ZHER2: 2891-Cys-MMA-DOTA ([68Ga] Ga-ABY-025) was shown to reflect HER2 …
Cleaved caspase-3 transcriptionally regulates angiogenesis-promoting chemotherapy resistance
A Bernard, S Chevrier, F Beltjens, M Dosset, E Viltard… - Cancer research, 2019 - AACR
Caspases are well known for their role in apoptosis. Recently, nonapoptotic roles of
caspases have been identified, however, these noncanonical roles are not well documented …
caspases have been identified, however, these noncanonical roles are not well documented …
Imaging approaches to optimize molecular therapies
Imaging, including its use for innovative tissue sampling, is slowly being recognized as
playing a pivotal role in drug development, clinical trial design, and more effective delivery …
playing a pivotal role in drug development, clinical trial design, and more effective delivery …
An integrated deep learning model for the prediction of pathological complete response to neoadjuvant chemotherapy with serial ultrasonography in breast cancer …
L Wu, W Ye, Y Liu, D Chen, Y Wang, Y Cui, Z Li… - Breast Cancer …, 2022 - Springer
Background The biological phenotype of tumours evolves during neoadjuvant
chemotherapy (NAC). Accurate prediction of pathological complete response (pCR) to NAC …
chemotherapy (NAC). Accurate prediction of pathological complete response (pCR) to NAC …
[HTML][HTML] Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis
Background The recommended preoperative approach for HER2-positive breast cancer is
unclear. We aimed to investigate the following: i) what is the optimal neoadjuvant regimen …
unclear. We aimed to investigate the following: i) what is the optimal neoadjuvant regimen …